Cargando…

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi(™), ENF) plus binimetinib (Mektovi(®), BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Patients treated with com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hefnawy, Mohamed M., Alanazi, Mohammed M., Al-Hossaini, Abdullah M., Alnasser, Abdulaziz I., El-Azab, Adel S., Jardan, Yousef A. Bin, Attwa, Mohamed W., El-Gendy, Manal A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822280/ https://www.ncbi.nlm.nih.gov/pubmed/36615272 http://dx.doi.org/10.3390/molecules28010079

Ejemplares similares

A Liquid Chromatography Tandem Mass Spectrometry Method for the Simultaneous Estimation of the Dopamine Receptor Antagonist LE300 and Its N-methyl Metabolite in Plasma: Application to a Pharmacokinetic Study
por: Hefnawy, Mohamed M., et al.
Publicado: (2023)

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

LC–MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study
por: Alnasser, Abdulaziz I., et al.
Publicado: (2023)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2021)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2022)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines
por: Patel, Vikas, et al.
Publicado: (2021)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
por: Huijberts, Sanne C. F. A., et al.
Publicado: (2020)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
por: Boccaccino, A., et al.
Publicado: (2022)

New bioanalytical microemulsion Electrokinetic chromatography method for the simultaneous determination of Trifluridine with its metabolites and Tipiracil in rat plasma: Application to pharmacokinetic studies
por: Hefnawy, Mohamed, et al.
Publicado: (2019)

Emerging Bioanalytical Devices and Platforms for Rapid Detection of Pathogens in Environmental Samples
por: Ngashangva, Lightson, et al.
Publicado: (2022)

Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation
por: Alanazi, Mohammed M., et al.
Publicado: (2019)

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
por: Kopetz, S., et al.
Publicado: (2022)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
por: Van Cutsem, Eric, et al.
Publicado: (2019)

Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
por: Abdelhameed, Ali S., et al.
Publicado: (2019)

Scopes of Bioanalytical Chromatography–Mass Spectrometry
por: Savelieva, E. I.
Publicado: (2021)

Validated Microwell-Based Spectrofluorimetric Method for Quantification of Ravidasvir (New Anti-Chronic Hepatitis C Virus-GT4) in Rat Plasma and Its Application to Pharmacokinetic Study
por: Hefnawy, Mohamed, et al.
Publicado: (2020)

Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry
por: Kadi, Adnan A., et al.
Publicado: (2018)

In Vitro Cytotoxic Potential of Selected Jordanian Flora and Their Associated Phytochemical Analysis
por: Alruwad, Manal I., et al.
Publicado: (2023)

Development and Validation of High-Throughput Bioanalytical Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Newly Synthesized Antitumor Carbonic Anhydrase Inhibitors in Human Plasma
por: Abdel-Megied, Ahmed M., et al.
Publicado: (2020)

Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application
por: Mohammed, Mostafa S., et al.
Publicado: (2021)

NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases
por: Kobayashi, Shin, et al.
Publicado: (2023)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Encorafenib overdose: Various toxicities: case report
Publicado: (2021)

Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation
por: Amer, Sawsan M., et al.
Publicado: (2017)

Reactive intermediates in naquotinib metabolism identified by liquid chromatography-tandem mass spectrometry: phase I metabolic profiling
por: Attwa, Mohamed W., et al.
Publicado: (2019)

BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2020)

Bioanalytical Method Development and Validation of Memantine in Human Plasma by High Performance Liquid Chromatography with Tandem Mass Spectrometry: Application to Bioequivalence Study
por: Konda, Ravi Kumar, et al.
Publicado: (2012)

Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells
por: Lee, Eunsung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_itgv7bt4kl3lt5e5e1tpkc5ska